

## Drotrecogin- $\alpha$ In Vitro Transcribed mRNA-LNP

Catalog Number:SG-MRNA-LNP-1913

DESCRIPTION	
Product Name	Drotrecogin- $\alpha$ In Vitro Transcribed mRNA-LNP
Gene Name	Drotrecogin- $\alpha$
Source	The ORF of Drotrecogin- $\alpha$ was cloned in our IVT vector and mRNA was prepared through in vitro transcription and purification. The purified mRNA was further encapsulated with LNP(DSPC:Cholesterol:DMG-PEG:SM102).
Alternative names	Drotrecogin- $\alpha$
SPECIFICATIONS	
Cap	m7GpppN
5'-UTR	5' -untranslated region derived from human alpha-globin RNA with an optimized Kozak sequence
ORF	Drotrecogin- $\alpha$
3'-UTR	3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA
Poly(A) Tail	A 110-nucleotide poly(A)-tail consisting of a stretch of 30 adenosine residues, followed by a 10-nucleotide linker sequence and another 70 adenosine residues.
Modifications	N1-methyl-pseudouridine
Neutral Lipid	1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
Cholesterol	Cholesterol
Ionizable Lipid	1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
PEG-lipid	Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)
Storage	-20 °C
Buffer	PBS, pH7.4
Cryoprotectant	Trehalose
BACKGROUND	
Gene Accession	
Gene Alias	Drotrecogin- $\alpha$

protein S on platelet surfaces and then degrades factor Va and factor VIIIa, thereby reducing blood coagulability.

#### Background

Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Activated protein C combines with